Company profile
Positron Corporation
OTC: POSC · Healthcare · Medical - Devices
#937 of 1,418 Healthcare companies by revenue27th-percentile growth
EA Score
28DFH 17DQ —GM 45SS 58
v0.1 · 45/100 weight · provisional
↑ listing tenure, growth stability · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$444.8k
Rev growth YoY (TTM)
-23.5%
Net income (FY)
-$10.6M
Employees
10
as of 2026-08-20
Market cap
$58.5M
as of 2026-08-20
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$461.5k$461.5k2025
Net income-$10.6M-$10.6M2025
Operating income-$10.5M-$10.5M2025
Total assets$4.0M$4.0M2025
Liabilities$2.6M$2.6M2025
Equity$1.4M$1.4M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Positron Corporation’s revenue?
Positron Corporation booked $461.5k in FY2025 revenue, contracting 21% year over year — slower than 73% of Healthcare companies we track, at a -2297.8% net margin.
Peers · Healthcare
Imunon, Inc.39DBioelectronics Corporation——Pasithea Therapeutics Corp.32DSpeedus Corp.——Mangoceuticals, Inc.30DIntegrative Health Technologies, Inc.——Key facts
CEOAdel Abdullah
SectorHealthcare
IndustryMedical - Devices
HeadquartersNiagara Falls, NY
ExchangeOTC: POSC
Employees10
IPO date1999-08-09
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.